www.TheFinancialMarketingGroup.com
Followers | 59 |
Posts | 2,197 |
Boards Moderated | 4 |
Alias Born | 04/28/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$PAOG | #Goldman #SmallCap #Research Gives $0.015 PT +350% Upside #PAOGroup
PAO Group Inc .
(STOCK: PAOG )
Current Price: $0.0031
Goldman Small Cap Research Price Target:
$0.015
Float: 620M
About The Company
PAO Group , Inc. is an emerging cannabis and CBD company targeting growth via two tracks. The Company is in the early stages of developing a cannabis extract-based therapy to treat various respiratory diseases and illnesses, PAOG also owns a growing cannabis cultivation operation focused on hemp cultivation.
Investment Highlights:
Conclusion: PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones. Thus, we have now introduced a 12-month target of $0.015, a nearly 5x return from current levels
Future Developments: This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
Next steps include engaging a CRO to initiate the process for potential FDA approval of RespRx, its COPD treatment, representing an estimated $14.1B market by 2025. We expect this application to be fast-tracked, given that the use of CBDs to treat this disease is novel and based on a natural (and likely safer) product.
Price Target/ Higher Valuation: By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a $20M valuation, or a $0.015 price target. This targeted valuation is in line with IND-filling stocks. Moreover, with no long term debt on the books, PAOG has significant funding flexibility to continue on its R&D paths.
The Bullish Case For PAOG
Substantial Multi-Billion Dollar Market Opportunity
This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
Market analyst Goldman Small Cap Research slapped on a 12-month target of $0.015, a nearly 5x return from current levels.
The Bottom Line:
PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones.
This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a $20M valuation, or a $0.015 price target.
If you’re looking for a growth/ground floor opportunity in the multi-billion dollar CBD sector, PAOG if the opportunity you've been waiting for!By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
$PAOG | #Goldman #SmallCap #Research Gives $0.015 PT +350% Upside #PAOGroup
PAO Group Inc .
(STOCK: PAOG )
Current Price: $0.0031
Goldman Small Cap Research Price Target:
$0.015
Float: 620M
About The Company
PAO Group , Inc. is an emerging cannabis and CBD company targeting growth via two tracks. The Company is in the early stages of developing a cannabis extract-based therapy to treat various respiratory diseases and illnesses, PAOG also owns a growing cannabis cultivation operation focused on hemp cultivation.
Investment Highlights:
Conclusion: PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones. Thus, we have now introduced a 12-month target of $0.015, a nearly 5x return from current levels
Future Developments: This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
Next steps include engaging a CRO to initiate the process for potential FDA approval of RespRx, its COPD treatment, representing an estimated $14.1B market by 2025. We expect this application to be fast-tracked, given that the use of CBDs to treat this disease is novel and based on a natural (and likely safer) product.
Price Target/ Higher Valuation: By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a $20M valuation, or a $0.015 price target. This targeted valuation is in line with IND-filling stocks. Moreover, with no long term debt on the books, PAOG has significant funding flexibility to continue on its R&D paths.
The Bullish Case For PAOG
Substantial Multi-Billion Dollar Market Opportunity
This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
Market analyst Goldman Small Cap Research slapped on a 12-month target of $0.015, a nearly 5x return from current levels.
The Bottom Line:
PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones.
This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a $20M valuation, or a $0.015 price target.
If you’re looking for a growth/ground floor opportunity in the multi-billion dollar CBD sector, PAOG if the opportunity you've been waiting for!By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
$EVGN | #Evogene Ltd. Potential Breakout
Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.
$EVGN | #Evogene Ltd. Potential Breakout
Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.
$BNED | #BarnesAndNobleEducation, Potential 20% Upside
Barnes and Noble Education, Inc. engages in the management and operation of bookstore chains in universities. It operates through the following segments: Retail, Wholesale, and Digital Student Solutions (DSS). The Retail segment operates physical and virtual campus bookstores. The Wholesale segment sells hardware and software that provides inventory management and point-of-sale solutions to college bookstores. The DSS segment includes direct-to-student product and service offerings to assist students to study more effectively and improve academic performance. The company was founded by Leonard Riggio in 1965 and is headquartered in Basking Ridge, NJ.
$BNED | #BarnesAndNobleEducation, Potential 20% Upside
Barnes and Noble Education, Inc. engages in the management and operation of bookstore chains in universities. It operates through the following segments: Retail, Wholesale, and Digital Student Solutions (DSS). The Retail segment operates physical and virtual campus bookstores. The Wholesale segment sells hardware and software that provides inventory management and point-of-sale solutions to college bookstores. The DSS segment includes direct-to-student product and service offerings to assist students to study more effectively and improve academic performance. The company was founded by Leonard Riggio in 1965 and is headquartered in Basking Ridge, NJ.
$KTRA | #Kintara Therapeutics, Inc. On #Breakout #Alert
Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
$CNTY | #CenturyCasinos Bullish
Century Casinos, Inc. is an international casino entertainment company. The firm engages in the development and operation of gaming establishments as well as related lodging, restaurant, horse racing, and entertainment facilities. It operates through the following segments: Canada, United States, Poland, and Corporate and Other. The Canada, United States, and Poland segments include the operations of the company's properties in their respective geographical locations. The Corporate and Other segment consists of additional business activities including concession agreements, management agreements, consulting agreements, and certain other corporate and management operations. The company was founded by Erwin Haitzmann and Peter Hoetzinger in 1992 and is headquartered in Colorado Springs, CO.
$CNTY | #CenturyCasinos Bullish
Century Casinos, Inc. is an international casino entertainment company. The firm engages in the development and operation of gaming establishments as well as related lodging, restaurant, horse racing, and entertainment facilities. It operates through the following segments: Canada, United States, Poland, and Corporate and Other. The Canada, United States, and Poland segments include the operations of the company's properties in their respective geographical locations. The Corporate and Other segment consists of additional business activities including concession agreements, management agreements, consulting agreements, and certain other corporate and management operations. The company was founded by Erwin Haitzmann and Peter Hoetzinger in 1992 and is headquartered in Colorado Springs, CO.
$PRTK | #Paratek Pharmaceuticals, Breakout Target
Paratek Pharmaceuticals , Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.
$PRTK | #Paratek Pharmaceuticals, Breakout Target
Paratek Pharmaceuticals , Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.
$ZUMZ | #Zumiez Pops On Huge Earnings Beat
Earnings details - Source Investorplace
Zumiez (NASDAQ:ZUMZ) earnings for the clothing company’s second quarter of 2020 have ZUMZ stock soaring higher after-hours Thursday. That comes after reporting diluted earnings per share of $1. 01 on revenue of $250.39 million. Both of these are better than Wall Street’s estimates of 33 cents per share and revenue of $234.21 million.
Zumiez ( ZUMZ ) sign with bright white letters
Source: Sundry Photography / Shutterstock .com
Let’s take a deeper dive into the most recent Zumiez earnings report below.
Diluted per-share earnings are up 180.6% than the 36 cents reported in Q2 2019.
Revenue for the quarter comes in 9.6% higher than the $228.43 million reported during the same time last year.
Operating income of $33.11 million is a 183.7% improvement year-over-year from $11.67 million.
The Zumiez earnings report also has it bringing in a net income of $25.39 million.
That’s a 181.2% increase compared to the company’s net income of $9.03 million from the same period of the year prior.
$ZUMZ | #Zumiez Pops On Huge Earnings Beat
Earnings details - Source Investorplace
Zumiez (NASDAQ:ZUMZ) earnings for the clothing company’s second quarter of 2020 have ZUMZ stock soaring higher after-hours Thursday. That comes after reporting diluted earnings per share of $1. 01 on revenue of $250.39 million. Both of these are better than Wall Street’s estimates of 33 cents per share and revenue of $234.21 million.
Zumiez ( ZUMZ ) sign with bright white letters
Source: Sundry Photography / Shutterstock .com
Let’s take a deeper dive into the most recent Zumiez earnings report below.
Diluted per-share earnings are up 180.6% than the 36 cents reported in Q2 2019.
Revenue for the quarter comes in 9.6% higher than the $228.43 million reported during the same time last year.
Operating income of $33.11 million is a 183.7% improvement year-over-year from $11.67 million.
The Zumiez earnings report also has it bringing in a net income of $25.39 million.
That’s a 181.2% increase compared to the company’s net income of $9.03 million from the same period of the year prior.
$CRWD | #Crowdstrike Chart Review
CRWD has retraced to the local Fib Golden pocket and has had a small unconvincing bounce.
20ma momentum indicator remains as vital support.
Bulls need to reclaim the $132 level as support.
Bears will look to break $124 setting up a test of $117-$114 once again for support.
Indicators remain bearish
Valuation is a issue.
$CRWD | #Crowdstrike Chart Review
CRWD has retraced to the local Fib Golden pocket and has had a small unconvincing bounce.
20ma momentum indicator remains as vital support.
Bulls need to reclaim the $132 level as support.
Bears will look to break $124 setting up a test of $117-$114 once again for support.
Indicators remain bearish
Valuation is a issue.
$DOCU | #DocuSign #Bulls Should Be Concerned
Not a good close on Friday for DOCU , volume actually increased as selling supply was high.
Strong rejection off the 50ma.
Support levels to watch on Monday
$196.45 is weekly horizontal support
$191.00 is major volume shelf support, below
that level and capitulation is on the cards
For the optimists the 50ma must be reclaimed.
$DOCU | #DocuSign #Bulls Should Be Concerned
Not a good close on Friday for DOCU , volume actually increased as selling supply was high.
Strong rejection off the 50ma.
Support levels to watch on Monday
$196.45 is weekly horizontal support
$191.00 is major volume shelf support, below
that level and capitulation is on the cards
For the optimists the 50ma must be reclaimed.
$LEN | #Lennar Corp Long into Earnings
Lennar is Bullish coming into earnings .
Stock has back-tested the breakout level as support and bounced on high volume .
20ma is also now support.
Longs into earnings have defined risk at $71.00
Possible upside targets $85-$88
Daily Chart Analysis on NYSE & NASDAQ
$LEN | #Lennar Corp Long into Earnings
Lennar is Bullish coming into earnings .
Stock has back-tested the breakout level as support and bounced on high volume .
20ma is also now support.
Longs into earnings have defined risk at $71.00
Possible upside targets $85-$88
Daily Chart Analysis on NYSE & NASDAQ
$NVDA | #Nvidia - Weekly Chart Review
Decisive week ahead for NVDA , speculation that the deal to buy ARM is almost done,
may bring some much needed momentum.
Bulls need to hold $468 and reclaim the 20ma and $505.
Stochastic does look to have bottomed while the
RSI is sitting on long term uptrend support.
If market remains bearish expect the 50ma to get tested.
$NVDA | #Nvidia - Weekly Chart Review
Decisive week ahead for NVDA , speculation that the deal to buy ARM is almost done,
may bring some much needed momentum.
Bulls need to hold $468 and reclaim the 20ma and $505.
Stochastic does look to have bottomed while the
RSI is sitting on long term uptrend support.
If market remains bearish expect the 50ma to get tested.